Secondary hyperparathyroidism
Conditions
Brief summary
Normalization of PTH (and thus recovery of secondary hyperparathyroidism) at 2 years after diagnosis and start of treatment in one of the study groups. Secondary hyperparathyroidism will be defined as PTH at the upper limit or above the labs reference value combined with a normal or decreased serum calcium level (in patients with 25(OH)D >50 nmol/L
Detailed description
Decrease in BMD (defined as 3% decrease in T-score at the lumbar spine and 5% decrease in T-score at the hip / forearm), measured at 1 and 2 years after inclusion, Quality of life is measured after inclusion and thereafter every 6 months with the OBESI-Q questionnaire
Interventions
DRUGEtalpha 0
DRUG5 microgram zachte capsules
DRUG25 microgram zachte capsules
DRUGEtalpha 1 microgram zachte capsules
Sponsors
Academisch Ziekenhuis Leiden
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Normalization of PTH (and thus recovery of secondary hyperparathyroidism) at 2 years after diagnosis and start of treatment in one of the study groups. Secondary hyperparathyroidism will be defined as PTH at the upper limit or above the labs reference value combined with a normal or decreased serum calcium level (in patients with 25(OH)D >50 nmol/L | — |
Secondary
| Measure | Time frame |
|---|---|
| Decrease in BMD (defined as 3% decrease in T-score at the lumbar spine and 5% decrease in T-score at the hip / forearm), measured at 1 and 2 years after inclusion, Quality of life is measured after inclusion and thereafter every 6 months with the OBESI-Q questionnaire | — |
Countries
Netherlands
Outcome results
None listed